1-5 of 5
Sharon Supekar
Close
Sort by
Journal Articles

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke, Ansgar Weltermann, Seema Shah, Sharon Supekar, Luigi Di Caprio, Michele Baccarani
Journal: Blood
Blood (2021) 138 (Supplement 1): 635.
https://doi.org/10.1182/blood-2021-145611
Published: 2021
Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4160.
https://doi.org/10.1182/blood-2019-124710
Published: 2019
Journal Articles

Chronic Myeloid Leukemia Patients' Voice: Preliminary Results from the Italian Substudy of Enestpath (CAMN107AIC05), Exploring the Emotional Experience of Patients in the Context of Treatment-Free Remission

Lidia Borghi, PhD, Fausto Castagnetti, MD PhD, Franca Falzetti, MD, Massimiliano Bonifacio, MD, Enrico Capochiani, Francesca Lunghi, MD, Francesco Cavazzini, MD, Sara Galimberti, PhD MD, Claudia Minotto, Ester Maria Orlandi, MD, Simona Sica, MD, Claudia Galimberti, Jens Haenig, Sharon Supekar, Michele Baccarani, MD, Elena Vegni
Journal: Blood
Blood (2017) 130 (Supplement 1): 5654.
https://doi.org/10.1182/blood.V130.Suppl_1.5654.5654
Published: 2017
Journal Articles

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas CP Cross, MA, PhD, Andrzej Hellmann, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Almeida, MD PhD, Arpad Illes, MD PhD, Miguel Sagues, MD, Jens Haenig, PhD, Sharon Supekar, MSc, Seema Shah, MSc, Giuseppe Saglio, MD, Juan Luis Steegmann, MD, Michele Baccarani, MD
Journal: Blood
Blood (2016) 128 (22): 3094.
https://doi.org/10.1182/blood.V128.22.3094.3094
Published: 2016
Journal Articles

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Umberto Vitolo, MD, Marco Ladetto, Carola Boccomini, MD, Andrea Evangelista, Enrica Gamba, Eleonora Russo, Alessandra Tucci, Annalisa Chiarenza, Antonello Pinto, Amalia De Renzo, Francesco Zaja, Andrea Gallamini, MD, Alessia Bari, Isabel Alvarez, Elisa Bernocco, Mario Petrini, Guido Parvis, Benedetta Puccini, Paolo Corradini, Tommasina Perrone, Sharon Supekar, Annalisa Chiappella, Barbara Botto, MD, Barbara Mantoan, Federico De Angelis, Luca Baldini, MD, Giuseppe Rossi, MD
Journal: Blood
Blood (2011) 118 (21): 777.
https://doi.org/10.1182/blood.V118.21.777.777
Published: 2011